Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Drugs
Erschienen in: Drugs 5/2014

01.04.2014 | Adis Drug Evaluation

Pomalidomide: A Review of Its Use in Patients with Recurrent Multiple Myeloma

verfasst von: Lesley J. Scott

Erschienen in: Drugs | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Abstract

Oral pomalidomide (Imnovid® [EU]; Pomalyst® [USA]) in combination with dexamethasone (in the EU), is approved in several countries for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy (or progression within the last 60 days in the USA). The key therapeutic mechanisms of action of pomalidomide, a thalidomide analogue, reside in its immunomodulatory, antiproliferative and anti-angiogenic effects. In the pivotal, multinational phase II MM-002 and phase III MM-003 trials, pomalidomide plus low-dose dexamethasone was effective and had a manageable safety and tolerability profile in adult patients with relapsed and refractory multiple myeloma who had received at least two prior antimyeloma therapies, including at least 2 cycles of both lenalidomide and bortezomib. Moreover, compared with high-dose dexamethasone, treatment with pomalidomide plus low-dose dexamethasone significantly prolonged progression-free survival, overall survival and time to disease progression, and improved overall response rates in the intent-to-treat population. In general, improvements in these clinical outcomes with pomalidomide plus low-dose dexamethasone treatment were also observed in subgroups of patients, including those refractory to lenalidomide, bortezomib or both drugs, those who had received several prior antimyeloma therapies, patients with renal impairment, elderly patients and those with a high-risk cytogenetic profile. Thus, combination therapy with pomalidomide plus low-dose dexamethasone is an important emerging treatment option for use as salvage therapy in patients with relapsed and refractory multiple myeloma.
Literatur
1.
2.
3.
Harousseau JL, Dreyling M. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up [on behalf of ESMO Guidelines Working Group]. Ann Oncol. 2010;21(Suppl 5):v155–7.PubMedCrossRef
4.
5.
Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. New Eng J Med. 1999;341(21):1565–71.PubMedCrossRef
6.
Scott LJ, Lyseng-Williamson KA. Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma. Drugs. 2011;71(5):625–49.PubMedCrossRef
7.
Chanan-Khan A, Swaika A, Paulus A, et al. Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma. Blood Cancer J. 2013;3:e143.PubMedCentralPubMedCrossRef
8.
Shortt J, Hsu AK, Johnstone RW. Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy. Oncogene. 2013;32:4191–202.PubMedCrossRef
9.
Ruchelman AL, Man H-W, Zhang W, et al. Isosteric analogs of lenalidomide and pomalidomide: synthesis and biological activity. Bioorg Med Chem Lett. 2013;23(1):360–5.PubMedCrossRef
10.
Richardson PG, Mark TM, Lacy MQ. Pomalidomide: new immunomodulatory agent with potent antiproliferative effects. Crit Rev Oncol/Hematol. 2013;88(Suppl 1):S36–44.CrossRef
11.
Zhu YX, Kortuem KM, Stewart AK. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma. 2013;54(4):683–7.PubMedCentralPubMedCrossRef
12.
Zhu YX, Braggio E, Shi C-X, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood. 2011;118(18):4771–9.PubMedCentralPubMedCrossRef
13.
Ito T, Ando H, Suzuki T, et al. Identification of a primary target of thalidomide teratogenicity. Science. 2010;327(5971):1345–50.PubMedCrossRef
14.
Payvandi F, Wu L, Haley M, et al. Immunomodulatoy drugs inhibit expression of cyclooxygenase-2 from TNF-α, IL-1β, and LPS-stimulated human PMBC in a partially IL-10-dependent manner. Cell Immunol. 2004;230(2):81–8.PubMedCrossRef
15.
Ferguson GD, Jensen-Pergakes K, Wilkey C, et al. Immunomodulatory drug CC-4047 is a cell-type and stimulus-selective transcriptional inhibitor of cycloocygenase 2. J Clin Immunol. 2007;27(2):210–20.PubMedCrossRef
16.
Payvandi F, Wu L, Naziruddin SD, et al. Immunomodulatory drugs (IMiDs) increase the production of IL-2 from stimulated T cells by increasing PK-ϴ activation and enhancing the DNA-binding activity of AP-1 but not NF-κB, OCT-1, or NF-AT. J Interferon Cytokine Res. 2005;25(10):604–16.PubMedCrossRef
17.
Görgün G, Calabrese E, Soydan E, et al. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood. 2010;116(17):3227–37.PubMedCentralPubMedCrossRef
18.
Schey SA, Fields P, Bartlett JB, et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol. 2004;22(16):3269–76.PubMedCrossRef
19.
Dhodapkar K, Zhang L, Verma R, et al. Both intermittent and continuous dosing regimens of pomalidomide mediate broad activation of innate and adaptive immunity in relapsed/refractory myeloma: results of a phase II randomized trial [abstract no. 1949]. In: 55th American Society of Hematology Meeting and Exposition; 7–10 Dec 2013; New Orleans, LA.
20.
Fostier K, Corthais J, Heirman C, et al. Immunomodulatory drugs restore effector cell immune functions in myeloma patients with low disease burden after autologous stem cell transplantation [abstract no. 3214]. In: 55th American Society of Hematology Meeting and Exposition; 7–10 Dec 2013; New Orleans, LA.
21.
Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, et al. Pomalidomide and lenalidomide induce p21WAF−1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res. 2009;69(18):7347–56.PubMedCrossRef
22.
Verhelle D, Corral LG, Wong K, et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res. 2007;67(2):746–55.PubMedCrossRef
23.
Rychak E, Mendy D, Shi T, et al. Pomalidomide and dexamethasone are synergistic in preclinical models of lenalidomide-refractory multiple myeloma (MM) [abstract]. Clin Lymphoma Myeloma Leuk. 2013;13:S183.
24.
25.
Morgan GJ, Davies FE, Gregory WM, et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet. 2010;376:1989–99.PubMedCrossRef
26.
27.
Winter MC, Holen I, Coleman RE. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev. 2008;34(5):453–75.PubMedCrossRef
28.
Meiler SE, Wade M, Kutlar F, et al. Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice. Blood. 2011;118(4):1109–12.PubMedCentralPubMedCrossRef
29.
Moutouh-de Parseval LA, Verhelle D, Glezer E, et al. Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells. J Clin Invest. 2008;118(1):248–58.PubMedCentralPubMedCrossRef
30.
Andhavarapu S, Roy V. Immunomodulatory drugs in multiple myeloma. Expert Rev Hematol. 2013;6(1):69–82.PubMedCrossRef
31.
Anderson G, Gries M, Kurihara N, et al. Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood. 2006;107(8):3098–105.PubMedCrossRef
32.
Bolzoni M, Storti P, Bonomini S, et al. Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules. Exp Hematol. 2013;41(4):387–97.PubMedCrossRef
33.
Lopez-Girona A, Mendy D, Ito T, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide [Erratum appears in Leukemia. 2012 Nov; 26(11):2445]. Leukemia. 2012;26(11):2326–35.PubMedCentralPubMedCrossRef
34.
Thakurta A, Gandhi AK, Waldman MS, et al. Absence of mutation in cereblon (CRBN) and DNA damage binding protein 1 (DDB1) genes in myeloma cells and patients and its clinical significance [abstract]. Blood. 2013;122(21):3139.
35.
36.
Hoffmann M, Kasserra C, Reyes J, et al. Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration. Cancer Chemother Pharmacol. 2013;71(2):489–501.PubMedCentralPubMedCrossRef
37.
Kasserra C, Assaf M, Hoffmann M, et al. Evaluation of CYP450 and transporter-mediated drug–drug interaction potential of pomalidomide in healthy men and in vitro [abstract no. 1989]. In: 55th American Society of Hematology Meeting and Exposition; 7–10 Dec 2013; New Orleans, LA.
38.
Matous J, Siegel DSD, Duong HK, et al. MM-008 trial: pharmacokinetics (PK) and tolerability of pomalidomide plus low-dose dexamethasone (POM plus LoDEX) in relapsed/refractory multiple myeloma (RRMM) patients with renal impairment (RI) [abstract no. 8585]. J Clin Oncol. 2013;31(15 Suppl).
39.
Celegene Corporation. Efficacy and safety of pomalidomide and dexamethasone in RRMM patients with renal insufficiency [ClinicalTrials.gov identifier NCT02045017]. US National Institutes of Health, ClinicalTrials.gov. 2014. http://​www.​clinicaltrials.​gov. Accessed 4 Feb 2014.
40.
Celegene Corporation. A phase 2 multicenter, open-label study to determine the efficacy and safety of pomalidomide (CC-4047)in combination with low-dose dexamethasone in subjects with relapsed or refractory multiple myeloma with moderately or severely impaired renal function [Eudra CT identifier 2013-001903-36]. EU Clinical Trials Register, Clinicaltrialsregister.eu. 2013. https://​www.​clinicaltrialsre​gister.​eu Accessed 2 Feb 2014. .
41.
Richardson PG, Siegel DS, Vij R, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014. doi:10.​1182/​blood-2013-11-538835.
42.
San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(11):1055–66.PubMedCrossRef
43.
Weisel KC, Dimopoulos MA, Moreau P, et al. Pomalidomide plus low-dose dexamethasone (POM + LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): MM-003 analysis of patients (pts) with moderate renal impairment (RI) [abstract no. 8527]. J Clin Oncol. 2013;31(15 Suppl).
44.
Song KW, Dimopoulos MA, Weisel K, et al. Pomalidomide (POM) plus low-dose dexamethasone (LoDEX) improves health-related quality of life (HRQoL) vs high-dose dexamethasone (HiDEX) in relapsed refractory multiple myeloma (RRMM): patients enrolled in MM-003 phase 3 randomized trial [abstract no. 2939]. In: 55th American Society of Hematology Meeting and Exposition; 7–10 Dec 2013; New Orleans, LA.
45.
Dimopoulos MA, Weisel K, Song KW, et al. Final analysis, cytogenetics, long-term treatment, and long-term survival in MM003, a phase 3 study comparing pomalidomide + low-dose dexamethasone (POM + LoDEX) vs high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM) [abstract no. 408]. In: 55th American Society of Hematology Meeting and Exposition; 7–10 Dec 2013; New Orleans, LA.
46.
Weisel K, San Miguel JF, Song KW, et al. MM-003 phase 3 study of pomalidomide in combination with low-dose dexamethasone (POM + LoDEX) vs high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): POM + LoDEX is beneficial for elderly patients (>65 years of age) [abstract no. 3198]. In: 55th American Society of Hematology Meeting and Exposition; 7–10 Dec 2013; New Orleans, LA.
47.
San Miguel JF, Weisel K, Song KW, et al. Patient outcomes by prior therapies and depth of response: analysis of MM-003, a phase 3 study comparing pomalidomide + low-dose dexamethasone (POM + LoDEX) vs high-dose dexamethasone (HiDEX) in relapsed refractory multiple myeloma (RRMM) [abstract no. 686]. In: 55th American Society of Hematology Meeting and Exposition; 7–10 Dec 2013; New Orleans, LA.
48.
Leleu X, Attal M, Arnulf B, et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02. Blood. 2013;121(11):1968–75.PubMedCrossRef
49.
Leleu X, Karlin L, Marco M, et al. Pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma (RRMM) with deletion (del)17p and/or translocation t(4;14) [abstract no. 689]. In: 55th American Society of Hematology Meeting and Exposition; 7–10 Dec 2013; New Orleans, LA.
50.
Short KD, Rajkumar SV, Larson D, et al. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia. 2011;25(6):906–8.PubMedCentralPubMedCrossRef
51.
Lacy MQ, Kumar SK, LaPlant BR, et al. Pomalidomide plus low-dose dexamethasone (pom/dex) in relapsed myeloma: long term follow up and factors predicting outcome in 345 patients [abstract no. 201]. Blood. 2012;120(21).
52.
Mikhael JR, Hayman SR, Laumann K, et al. Long term outcomes of pomalidomide and dexamethasone in patients with relapsed multiple myeloma: analysis 4 years after the original cohort [abstract no. 2942]. Blood. 2011;118(21).
53.
Lacy MQ, LaPlant BR, Laumann K, et al. Pomalidomide and dexamethasone in relapsed myeloma: results of 225 patients treated in five cohorts over three years [abstract no. 3963]. Blood. 2011;118(21).
54.
Cooney MM, Nock C, Bokar J, et al. Phase I trial of pomalidomide given for patients with advanced solid tumors. Cancer Chemother Pharmacol. 2012;70(5):755–61.PubMedCrossRef
55.
Richardson PG, Siegel D, Baz R, et al. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood. 2013;121(11):1961–7.PubMedCrossRef
56.
Lacy MQ, Allred JB, Gertz MA, et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood. 2011;118(11):2970–5.PubMedCentralPubMedCrossRef
57.
Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia. 2010;24(11):1934–9.PubMedCentralPubMedCrossRef
58.
Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol. 2009;27(30):5008–14.PubMedCrossRef
59.
Celgene Corporation. MTD, safety, and efficacy of pomalidomide (CC-4047) alone or with low-dose dexamethasone in patients with relapsed and refractory multiple myeloma [ClinicalTrials.gov identifier NCT00833833]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://​www.​clinicaltrials.​gov. Accessed 4 Nov 2013.
60.
Jagannath S, Hofmeister CC, Baz RC, et al. Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM): MM-002 phase II age subgroup analysis [abstract no. 8532]. J Clin Oncol. 2013;31(15 Suppl).
61.
Siegel DS, Richardson PG, Baz R, et al. Pomalidomide (POM) with low-dose dexamethasone (LoDEX) in patients with relapsed and refractory multiple myeloma (RRMM): impact of renal function on patient outcomes [abstract no. 4072]. Blood. 2012;120(21).
62.
Bladé J, Rosiñol L, Cibeira MT. Prognostic factors for multiple myeloma in the era of novel agents. Ann Oncol. 2008;19(Suppl 7):vii117–20.
63.
Mikhael JR, Roy V, Richardson PG, et al. A phase I/II trial of pomalidomide, bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma [abstract no. 1940]. In: 55th American Society of Hematology Meeting and Exposition; 7–10 Dec 2013; New Orleans, LA.
64.
Richardson PG, Hofmeister CC, Siegel D, et al. MM-005: a phase I trial of pomalidomide, bortezomib and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM) [abstract no. 1969]. In: 55th American Society of Hematology Meeting and Exposition; 7–10 Dec 2013; New Orleans, LA.
65.
Shah JJ, Stadtmauer EA, Abonour R, et al. Phase I/II dose expansionof a multi-center trial of carfilzomib and pomalidomide with dexamethasone (Car-Pom-dS) in patients with relapsed/refractory multiple myeloma [abstract no. 690]. In: 55th American Society of Hematology Meeting and Exposition; 7–10 Dec 2013; New Orleans, LA.
66.
Baz R, Martin TG, Alsina M, et al. Pomalidomide (Pom) dexamethasone (D) with or without oral weekly cyclophosphamide (Cy) for lenalidomide refractory multiple myeloma (LRMM): a multicenter randomized phase II trial [abstract no. 3200]. In: 55th American Society of Hematology Meeting and Exposition; 7–10 Dec 2013; New Orleans, LA.
67.
Berenson JR, Hilger JD, Klein L, et al. Pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed/refractory multiple myeloma: results from a phase 1/2 trial [abstract no. 3218]. In: 55th American Society of Hematology Meeting and Exposition; 7–10 Dec 2013; New Orleans, LA.
68.
Celegene Corporation. Safety and efficacy of pomalidomide, bortezomib, and low-dose dexamethasone in subjects with relapsed or refractory multiple myeloma (OPTIMISMM) [ClinicalTrials.gov identifier NCT01734928]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://​www.​clinicaltrials.​gov. Accessed 22 Nov 2013.
Metadaten
Titel
Pomalidomide: A Review of Its Use in Patients with Recurrent Multiple Myeloma
verfasst von
Lesley J. Scott
Publikationsdatum
01.04.2014
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 5/2014
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-014-0196-6

Weitere Artikel der Ausgabe 5/2014

Drugs 5/2014 Zur Ausgabe

Systematic Review

Meta-Review: Adverse Effects of Inhaled Corticosteroids Relevant to Older Patients

Adis Drug Evaluation

Vildagliptin: A Review of Its Use in Type 2 Diabetes Mellitus

Current Opinion

Omalizumab for Severe Asthma: Efficacy Beyond the Atopic Patient?

Adis Drug Evaluation

Delta-9-Tetrahydrocannabinol/Cannabidiol (Sativex®): A Review of Its Use in Patients with Moderate to Severe Spasticity Due to Multiple Sclerosis

R&D Insight Report

Ipragliflozin: First Global Approval

Adis Drug Evaluation

Radium-223 Dichloride: A Review of Its Use in Patients with Castration-Resistant Prostate Cancer with Symptomatic Bone Metastases